Rather than challenging the value of colonoscopy, Dr. Paul Limburg argues that the U.S. can no longer rely on it as the primary colorectal cancer screening strategy. With nearly 60 million Americans eligible for screening but capacity for only about 15 million colonoscopies annually, the healthcare system faces a widening gap that could delay cancer detection and treatment.
Drawing on new modeling studies and the 2026 American Cancer Society screening guideline, the article makes the case for a complementary approach: use next-generation multitarget stool DNA (mt-sDNA) tests for initial screening in average-risk patients, while reserving colonoscopy for diagnostic follow-up and therapeutic procedures. According to the analysis, this strategy could detect more colorectal cancers, prevent more deaths, reduce healthcare costs, and free gastroenterologists to perform higher-value procedures.
Key takeaway: The article argues that the future of colorectal cancer screening is not colonoscopy versus noninvasive testing—it is using both strategically to expand screening access and save more lives.